Over the past 3 months, 5 analysts have published their opinion on Crinetics Pharmaceuticals CRNX stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.
|Bullish||Somewhat Bullish||Indifferent||Somewhat Bearish||Bearish|
These 5 analysts have an average price target of $38.2 versus the current price of Crinetics Pharmaceuticals at $16.62, implying upside.
Below is a summary of how these 5 analysts rated Crinetics Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This average price target has increased by 9.14% over the past month.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.